Kornimate/medical-research-clean huggingface dataset:
the comparison of remimazolam with propofol in core body temperature

Conditions: Hypothermia; Anesthesia

Summary: 1. core body temperature is normally tightly regulated to within a few tenths of a degree. the major thermoregulatory defences in humans are sweating, arteriovenous shunt vasoconstriction, and shivering. 2. inadvertent hypothermia often complicates prolonged surgery. in patients becoming sufficiently hypothermic, reemergence of thermoregulatory vasoconstriction usually prevents further core hypothermia. 3. the extent to which anesthetics reduce the vasoconstriction threshold depends on the type of drug and its concentration.

1. when propofol induces anesthesia, blood pressure decreases due to vasodilation, which is due to direct action on vascular smooth muscle and vasodilation due to blockage of the sympathetic nervous system. this results in a redistribution of body temperature, resulting in hypothermia. 2. the effects of remimazolam on the central nervous system, respiratory and cardiovascular system have been studied. remimazolam, a new type of benzodiazepine drug acts on the gaba-a receptor and has the advantages of rapid induction, rapid recovery, stable hemodynamics, and mild respiratory inhibition. at present, there is little literature on its practice in intraoperative thermoregulation under general anesthesia. 3. investigators hypothesized that the type of anesthetic agents might affect thermoregulatory mechanisms such as the redistribution of body heat, cutaneous heat loss or inhibition of thermoregulatory vasoconstriction. therefore, investigators investigated to compare remimazolam with propofol in core body temperature, vasoconstriction threshold and times to onset of vasoconstriction(min)in patients given laparoscopic assisted vaginal hysterectormy.

Eligibility criteria:
inclusion criteria: 1. asa physical classification i-iii, 2. patients who undergoing robotic-assisted or laparoscopic (lrp) radical prostatectomy. exclusion criteria: 1. patients who have medications or any implanted device that could affect cardiovascular function 2. patients who have a history with heat imbalance, thyroid diseases, dystautonomia, raynaud's syndrome, uncontrolled diabetes mellitus, or hypertension.

Keywords: hypothermia vasoconstriction threshold propofol remimazolam
comparison of gabapentin and metoclopramide for treating hyperemesis gravidarum

Conditions: Hyperemesis Gravidarum

Summary: the investigators will compare the effectiveness of gabapentin to metoclopramide for 1 week among 60 women with hyperemesis gravidarum (hg) in this randomized, double-blinded trial. after completion of the 1-week double-blind phase, subjects will be offered open-label gabapentin with rescue metoclopramide until their symptoms no longer require treatment. enrollment will occur at the university's at buffalo, of rochester and of wisconsin.


Eligibility criteria:
inclusion criteria: 1. have received at least 2 administrations of intravenous (iv) hydration separated by at least 1 week or daily emesis for at least the last 14 days and 1 administration of iv hydration. 2. have at least one of the following: 2-4+ ketonuria, serum potassium \ 5% weight loss from weight upon entry to prenatal care. 3. have failed therapy with at least one antiemetic. 4. have fetal ultrasound within 6 weeks prior to enrollment confirming a normal-appearing, intrauterine, singleton pregnancy of gestational age \< 16 weeks at time of enrollment. 5. felt by the patient's obstetrician or emergency room attending physician not to have other medical problems such as bowel obstruction, pancreatitis, biliary colic, or peptic ulcer disease that could be contributing to the patient's symptoms. 6. be \>18 years old and not decided to terminate the pregnancy. 7. have not received or planning to receive a peripherally inserted central catheter (pic line). 8. have a motherisk-puqe score of ≥12 for the 24-hour baseline period. 9. felt not to have any other significant medical, psychiatric or substance abuse problem that would preclude participation in the study. 10. denies drinking any alcohol after learning about current pregnancy. 11. agrees to discontinue any current anti-emetic treatments (including antihistamines, ginger, \> 10mg/day vitamin b6, serotonin or dopamine antagonists, anticholinergics, acupuncture, hypnosis, or wrist bands) for the next 4 weeks. 12. pregnancy not conceived through in-vitro fertilization. 13. able to understand and comply with the study procedures and give informed consent. exclusion criteria: none not mentioned under inclusion criteria.

Keywords: pregnancy nausea vomiting hyperemesis treatment gabapentin metoclopramide safety
a registry study on biomarkers of pulmonary embolism

Conditions: Pulmonary Embolism

Summary: the purpose of the study is to evaluate the value of biomarkers in the diagnosis and risk stratification of patients with suspected pulmonary embolism.

management of patients with acute pulmonary embolism is a serious problem. the rapid and accurate diagnosis and risk stratification of these patients is an important unmet clinical need. the aim of the study is to evaluate the value of biomarkers, alone or in combination, in the diagnosis and risk stratification of patients with suspected pulmonary embolism presenting to the emergency department.

Eligibility criteria:
inclusion criteria: * patient aged ≥ 18 years that presents to an emergency department * with suspected pe defined as new onset of or worsening of shortness of breath or chest pain exclusion criteria: * hemodynamic instability * life expectancy less than 3 months * first symptoms 15 day or more before inclusion * inability to the follow-up visits * therapeutic anticoagulation for any indication
cognitive impairment, retinopathy, and cerebrovascular lesions in the elderly

Conditions: Cerebral Small Vessel Diseases; Retinopathy; Cognitive Dysfunction

Summary: the circle study is a single-center prospective observational study that enrolled individuals with cerebral small vessel disease (svd), while free of known dementia or stroke (both cerebral infarction and hemorrhage). the patients will receive neuropsychological testing, retinal digital images and multimodal magnetic resonance imaging (mri). blood samples will also be collected. recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and brain atrophy will be evaluated on both baseline and follow-up brain mris. the investigators will explore the predictors of preogression of svd and cognitive deficits.

cerebral small vessel disease (svd) is commonly detected in elderly individuals, and patients with stroke or neurodegenerative disease. features seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and brain atrophy. previous studies indicated that svd was associated with an increased risk of stroke and stroke recurrence, cognitive deficits, physical disabilities, and mortality. however the pathogenesis of svd is largely unknown. little is known about how svd lesions contribute to neurological or cognitive symptoms, and the association with risk factors. recent data sugessted concomitant svds and retinopathy is associated with a profile of vascular cognitive impairment. in this study, the investigators try to explore the new pathological mechanism of svd, the new predictors for svd progression, and the association with cognitive impairment, based on digital retinal images and brain multimodal imaging technique.

Eligibility criteria:
inclusion criteria: * adult (≥40y; no upper limit) * free of known dementia or stroke (both cerebral infarction and hemorrhage) exclusion criteria: * any mri contraindications * serious head injury (resulting to loss of consciousness) or received intracranial surgery * suffering from cancer
a randomized controlled trial of a multicomponent walking aid program for people with ms

Conditions: Multiple Sclerosis

Summary: this is a randomized controlled trial of the assistive device selection, training, and education program (adstep). adstep is a training program of six weekly one-on-one sessions with a physical therapist intended to reduce falls among people who use a hand-held walking aid, such as a cane or a walker. adstep focuses on training in the use of the walking aid, and includes gait evaluation, walking aid selection and fitting, and progressive task-oriented training with the walking aid. participants will be randomized to receive adstep or a waitlist control intervention; those in the control condition will receive national ms society brochures on fall prevention and walking aid selection, and a letter will be sent informing their care provider that the subject reports falling. all subjects will complete an assessment visit at baseline, and follow-up assessments at about 8 weeks and about 6 months after that. subjects will complete paper questionnaires of patient reported outcomes (pros), a modified functional gait assessment / dynamic gait index, and will track fall sustained over their participation in the study using monthly paper fall calendars. at the end of study participation, all subjects in the control group will be offered the opportunity to receive adstep.


Eligibility criteria:
inclusion criteria: 1. a definite diagnosis of ms of any type; 2. 18 years of age or older; 3. self-reported history of at least one fall in the previous year; 4. ability to walk at least 25 feet with or without an assistive device; 5. intermittent or constant unilateral or bilateral assistance required to walk; 6. no ms exacerbations for the past 30 days; 7. willingness to complete a written daily record of falls for about 8 months. exclusion criteria: 1. currently receiving physical therapy, or having any plans to receive physical therapy in the upcoming 8 months (duration of study participation); 2. serious psychiatric or medical conditions that would preclude reliable participation in the study (e.g. dementia, deafness, blindness); 3. inability to follow directions in english.

Keywords: fall prevention walking aid physical therapy
deep neuromuscular relaxation in patients for thoraco-laparoscopic esophagectomy

Conditions: Neuromuscular Block; Esophageal Cancer; Surgery

Summary: rationale: endoscopic (thoraco-laparoscopic) esophageal surgery is a high risk procedure where the use of deep neuromuscular block (nmb) may increase field visibility and anaesthesia conditions. under these conditions, boluses of muscle relaxants can be given on indication only or by continuous infusion. we hypothesize that deep nmb by continuous infusion of rocuronium as compared to on demand bolus administration facilitates surgical and anesthesia conditions during thoraco-laparoscopic esophageal resection but higher doses of sugammadex are needed to reverse nmb at the end of surgery. objective: primary objective is to evaluate the use of deep muscle relaxation versus on indication only on surgical and anesthesia conditions in patients for endoscopic esophageal resection. secondary objectives are to evaluate the (hypothetical) dose of sugammadex needed in both groups in an economical perspective and to compare the intra-operative cardiac and respiratory incidents and post-operative complication rate of both groups. study design: a single-center randomized controlled double-blinded intervention study. study population: all patients \> 18 years to undergo a thoracolaparoscopic esophageal resection.i intervention: patients are randomized to receive either continuous infusion of rocuronium 0.6 mg/kg/hr (group 1) or continuous infusion of nacl 0.9% 0.06 ml/kg/hr (group 2). on demand boluses of rocuronium 0.3 mg/kg can be given in both groups. main study parameters/endpoints: the primary outcome parameter of this study is the srs during the abdominal phase of thoracolaparoscopic esophageal surgery. secondary outcomes measured are srs during the thoracic phase, the number of on demand boluses infused, the dose of sugammadex needed in both groups to reach a tof of \> 90%, duration of surgery, a cost-analysis, the incidence of intra-operative cardiac and respiratory incidents and the ability of surgeons to estimate which neuromuscular blocking regime was given to the patient.


Eligibility criteria:
inclusion criteria: * patients, undergoing elective thoraco-laparoscopic esophageal resection (either ivor lewis or mckeown variant) * written informed consent exclusion criteria: * pregnancy * known allergies for aminosteroid-type muscle relaxants or sugammadex. * severe kidney dysfunction (gfr \< 30), patients on dialysis * liver function disorders * myasthenia gravis or other (neuro)muscular diseases * patients with carcinomatosis * use of anti-epileptics and lithium or drugs containing kinin

Keywords: surgical rating scale neuromuscular relaxation anaesthesia minimally invasive esophagectomy
evaluation of state and shade of white spot lesions after using different remineralizing agents (an in vivo study)

Conditions: White Spot Lesion

Summary: the aim of the study is to evaluate the effect of biomimetic remineralizing agent and resin modified glass ionomer varnish on color shade and state of white spot lesions immediately, after 3 months, and after 6 months. (an in vivo study).


Eligibility criteria:
inclusion criteria: 1. patients included in this clinical trial were less than 30 years old. 2. patients with good general health. 3. patients who will agree to the consent and will commit to follow-up period. 4. fully erupted anterior teeth with no cavitated lesions. exclusion criteria: 1. patients with any systemic disease that may affect normal healing. 2. patient with bad oral hygiene. 3. tetracycline or florosis staining. 4. patients who could/would not participate in all times of follow-up. 5. untreated periodontal disease was not allowed. 6. active caries or defective restorations in 6 anterior teeth. 7. bleaching history 8. patients participating in more than 1 dental study. 9. patient received fluoride varnish before.
treating pre-school children at risk for overweight in the primary care setting

Conditions: Overweight

Summary: the goal of this study is to test, in the primary care setting, the efficacy of an innovative intervention program for children aged 2-5 years with a bmi over the 85th percentile and one overweight parent (bmi \>27 kg/m2.


Eligibility criteria:
inclusion criteria: * 2-5 year old with a bmi greater than the 85th% for age and sex * one overweight parent (bmi\>27kg/m2) * child with normal developmental milestones * history of adherence to 90% of scheduled primary care visits * parent must be at 5th grade reading and speaking of english language or the spanish language * no plans on moving out of the area for the 2 years subsequent to enrollment exclusion criteria: * child with a height 2 sd below the mean for age and sex and/or pathological growth velocity * sga * any chronic disorders influencing energy intake and/or growth * any orthopedic disorder preventing the child or the parent from ambulation normally and performing the activity prescribed by the program * any medication known to have the potential of affecting weight changes * parent or child with psychiatric and/or eating disorder * participating mother who is pregnant or planning a pregnancy * parent being acquainted with the parent of a previously randomized study participant

Keywords: bmi >85%for age and gender
the prescription patterns and clinical efficacy of tenero tab/tenero m sr tab

Conditions: Diabetes Mellitus, Type 2

Summary: this study is to observe the prescription patterns and clinical efficacy of patients prescribed with tenero tab/tenero m sr tab for diabetes treatment in routine clinical practice.

this study is to observe the clinical efficacy by analyzing the prescription patterns in routine clinical practice and changes in hba1c, fpg, pp2g, etc., of patients prescribed with tenero tab/tenero m sr tab for diabetes treatment. additionally, the study intends to assess patient satisfaction based on these observations.

Eligibility criteria:
inclusion criteria: 1. adults over 19 years of age 2. individuals diagnosed with type 2 diabetes. 3. individuals who, at the clinical discretion, are prescribed tenero tab or tenero m sr tab for the purpose of diabetes treatment for the first time. 4. individuals who have voluntarily provided written consent to participate in this study. exclusion criteria: 1. pregnant or breastfeeding women. 2. individuals who are contraindicated according to the approved indications of tenero tab/tenero m sr tab. 3. other cases where the principal investigator and study personnel deem individuals ineligible for participation in this clinical trial.

Keywords: metformin hci teneligliptin hydrochloride
fibroscan ® study: assessing liver fibrosis in patients using methotrexate for psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to validate fibroscan and fibrosure™ as equal or superior alternatives to liver biopsy for the monitoring and detection of methotrexate-induced hepatic fibrosis and cirrhosis in patients with moderate-to-severe psoriasis.

the goals of this study are to validate fibroscan and fibrosure™ as equal or superior alternatives to liver biopsy. the goal is to evaluate the monitoring and detection of methotrexate-induced hepatic fibrosis and cirrhosis in patients with moderate-to-severe psoriasis.

Eligibility criteria:
inclusion criteria: * male or female greater than or equal to 18 years of age * must have a diagnosis of moderate-to-severe psoriasis * newly starting methotrexate exclusion criteria: * allergy to methotrexate * history of chronic alcohol abuse * diagnosis of liver disease

Keywords: methotrexate fibroscan fibrosure cirrhosis fibrosis
research of intensive lifestyle intervention for pcos patients with igt

Conditions: Polycystic Ovary Syndrome

Summary: compare the efficacy between intensive lifestyle intervention and drugs (glp-1 receptor agonists, metformin and acarbose) for pcos patients with early onset diabetes in their metabolic and reproductive abnormalities treatment; clear the treatment effect and mechanism of intensive lifestyle intervention to pcos.

we designed a non randomized control study to compare the efficacy between intensive lifestyle intervention and drugs (glp-1 receptor agonists, metformin and acarbose) for pcos patients with early onset diabetes in their metabolic and reproductive abnormalities treatment we planed to enroll 48 patients.overweight and obese pcos patients with newly diagnosed igt; pcos diagnosis based on 1990 nih criteria. overweight / obesity diagnostic criteria according to who-wpr. igt diagnostic criteria according to 1998 who diagnostic criteria. except for serious complications (cardiovascular events and recent significant kidney or lung disease within 3 months), and had high blood pressure (\>160/100mmhg), blood sugar and high blood lipids (glycated hemoglobin\> 11%, triglycerides \>600 mg/dl). then we devided the 48 patients into 4 groups: intensive lifestyle intervention group, glp-1 group, metformin group and acarbose group, and each group 12 samples. each group use specific treatment(showed as the group name) 3 months. before and after the intervention, the blood samples would be collected to glucose, insulin, glp-1, glucagon, sex hormones, blood chemistry for liver and kidney function ect, as well as the image examinations. we will compare the data of each patient, finally identify the treatment effect and mechanism of intensive lifestyle intervention to pcos.

Eligibility criteria:
inclusion criteria: * overweight and obese pcos patients with newly diagnosed igt; pcos diagnosis based on 1990 nih criteria. overweight / obesity diagnostic criteria according to who-wpr. igt diagnostic criteria according to 1998 who diagnostic criteria. exclusion criteria: * except for serious complications (cardiovascular events and recent significant kidney or lung disease within 3 months), and had high blood pressure (\>160/100mmhg), blood sugar and high blood lipids (glycated hemoglobin\> 11%, triglycerides \>600 mg/dl).

Keywords: pcos intensive lifestyle intervention igt drugs treatment
stored rbc transfusion and immonomodulation

Conditions: Infections

Summary: transfusion of rbc is associated with post operative infections. our hypothesis is that stored blood could be related with increased post operative infection risk. surgical patients transfused during the operation or immediately after will be included in our study. patients will receive fresh or old blood during the whole recovery.


Eligibility criteria:
inclusion criteria: * patients transfused during or in 24h after surgical operation exclusion criteria: * patients transfused during the 30 days before the operation * immunodepressed patients * infections during the 30 days before operations * emergency surgery
predicting arrhythmogenic risk in congenital heart patients: the precision study

Conditions: Arrhythmia in Children; Congenital Heart Disease

Summary: in this research study we want to learn more about abnormal heart rhythm after cardiac surgery in children. these abnormal heart rhythms, also called arrhythmias, may occur due to several reasons after cardiac surgery. they can be due to abnormal electrical pathway or an irritable area of the heart that stimulates abnormal impulses. regardless of the cause, arrhythmias after cardiac surgery can be a problem, extending the hospital stay, requiring additional medications and even leading to cardiac arrest. current practice is to monitor for arrhythmias after cardiac surgery, and to treat them if they occur. with this research, we want to investigate whether we can identify patients who will develop arrhythmia, and treat them before they occur.

this is a prospective, randomized controlled trial of provocative electrophysiology testing and prophylactic treatment of inducible svt versus expectant management

Eligibility criteria:
inclusion criteria: * patients aged \ 10% exclusion criteria: * patients following orthotopic heart transplant, ventricular assist device implantation, primary extracorporeal membrane oxygenation cannulation, pacemaker or implantable cardioverter-defibrillator implantation or sympathectomy * patients on antiarrhythmic medication at the time of surgery * patients with atrioventricular conduction disease (1st degree atrioventricular block with pr interval greater than 200 ms, 2nd degree atrioventricular block or complete heart block) * patients with severe ventricular dysfunction in whom therapy with beta-blocker or sotalol is deemed contra-indicated by the primary team * patients with absent or non-functioning atrial pacing wires
early detection of alzheimer's disease and affective disorders by automated voice and speech analysis (plata)

Conditions: Neurocognitive Disorders

Summary: plata aims to develop an algorithm to identify vocal biomarkers of alzheimer's dementia. using data collected as part of routine care, speech patterns will be compared to known biomarkers of alzheimer's disease, such as amyloid 1-42 and p-tau in csf (cerebrospinal fluid). if biomarkers of speech can be identified in alzheimer's disease, it is possible that patients and research participants will no longer need to undergo need to undergo the intensive and invasive baseline biomarker methods currently used, such as lumbar punctures and pet scans.


Eligibility criteria:
inclusion criteria: * age ≥ 50 years * diagnosis relevant biomarker and neuropsychological data already available * cognitively healthy to very mild dementia (cdr score max. 0.5) * sufficient knowledge of the study language to understand study information, non opposition form,and questionnaires * expression of non opposition exclusion criteria: * hearing problems * patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article l.1121-16 of the french public health code

Keywords: alzheimer's disease mood disorder